Ovid Therapeutics (OVID) Net Income towards Common Stockholders (2016 - 2026)

Ovid Therapeutics (OVID) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$17.0 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 65.98% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.2 million (up 3.23% YoY) and the FY2025 annual result came in at -$17.4 million, up 34.12% from the prior year.
• Net Income towards Common Stockholders declined to -$17.0 million in Q1 2026, from $9.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.7 million in Q4 2025 to a low of -$17.0 million in Q1 2026.
• A 5-year average of -$9.8 million and a median of -$12.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 204.43% in 2025, down 154.97% in 2025.
• Tracing OVID's Net Income towards Common Stockholders over 5 years: stood at -$11.5 million in 2022, then sank by 33.18% to -$15.3 million in 2023, then soared by 39.61% to -$9.3 million in 2024, then soared by 204.43% to $9.7 million in 2025, then slumped by 275.8% to -$17.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$17.0 million (Q1 2026), $9.7 million (Q4 2025), and -$12.2 million (Q3 2025), per Business Quant data.